Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Europe and Israel or involving organisations from these countries.

Total search results: 8201 | Ordered by Date (descending)
1 2 3 ... 81 82 83  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Nuuron–SEVERAL: investment, 202410 seed financing round €3.5m led by HTGF 2024-10-31
Aignostics–Berlin (govt): investment, 202410 financing round Series B totalling $34m incl existing + co-investor VC Fonds Technologie 2024-10-29
Aignostics–Boehringer: investment, 202410 financing round Series B totalling $34m incl existing + co-investor BIVF 2024-10-29
Aignostics–Carma Fund: investment, 202410 financing round Series B totalling $34m incl existing + co-investor Carma Fund 2024-10-29
Aignostics–High-Tech Gründerfonds: investment, 202410 financing round Series B totalling $34m incl existing + co-investor HTGF 2024-10-29
Aignostics–Mayo Clinic: AI-based diagnostics, 202410 collab developm foundation models for digital pathology 2024-10-29
Aignostics–Mayo Clinic: investment, 202410 financing round Series B totalling $34m incl co-investor Mayo Clinic 2024-10-29
Aignostics–SEVERAL: investment, 202410 financing round Series B $34m led by Athos 2024-10-29
Aignostics–Strüngmann Group: investment, 202410 financing round Series B totalling $34m incl lead investor Athos 2024-10-29
Aignostics–Wellington Partners: investment, 202410 financing round Series B totalling $34m incl existing + co-investor Wellington Partners 2024-10-29
Inbrain Neuroelectronics–SEVERAL: investment, 202410 financing round Series B $50m led by imec.xpand 2024-10-29
Kynos Therapeutics–Falk Pharma: investment, 202410 acquisition of Kyno Therapeutics Ltd by Dr Falk Pharma GmbH 2024-10-29
Kivu Bioscience–BioGeneration Ventures: investment, 202410 financing round Series A totalling $92m incl existing + co-investor BGV 2024-10-28
Kivu Bioscience–Gimv: investment, 202410 financing round Series A totalling $92m incl new + co-investor Gimv 2024-10-28
Kivu Bioscience–Lonza: ADC technology, 202410 existent use of GlycoConnect platform fo Synaffix by Kivu Bioscience 2024-10-28
Kivu Bioscience–Merck (DE): investment, 202410 financing round Series A totalling $92m incl existing + co-investor M Ventures 2024-10-28
Kivu Bioscience–Netherlands (govt): investment, 202410 financing round Series A totalling $92m incl existing + co-investor BOM 2024-10-28
Kivu Bioscience–Novo Group: investment, 202410 financing round Series A totalling $92m incl lead investor Novo Holdings 2024-10-28
Kivu Bioscience–Odlander Fredrikson: investment, 202410 financing round Series A totalling $92m incl new + co-investor HealthCap 2024-10-28
Kivu Bioscience–SEVERAL: investment, 202410 financing round Series A $92m led by Novo Holdings 2024-10-28
Nuclera–SEVERAL: investment, 202410 financing round $75m led by Elevage Medical Technologies (Patient Square Capital) 2024-10-16
Invios–SEVERAL: investment, 202410 financing round Series A €8.2m incl existing investors + Ligand Pharmaceuticals 2024-10-15
Booster Therapeutics–Apollo Health Ventures: investment, 202410 seed financing round totalling $15m incl co-lead investor Apollo Health Ventures 2024-10-10
Booster Therapeutics–Novo Group: investment, 202410 seed financing round totalling $15m incl co-lead investor Novo Holdings 2024-10-10
Booster Therapeutics–SEVERAL: investment, 202410 seed financing round $15m led by Apollo Health Ventures + Novo Holdings 2024-10-10
Immatics–SEVERAL: investment, 202410– proposed public offering $150m 2024-10-10
Lumicks–EU (govt): credit, 202410– venture debt financing €20m from EIB to advance high-througput cell avidity platform 2024-10-10
a:head bio–SEVERAL: investment, 202410 financing round pre-Series A 7-digit EUR from existing + new investors 2024-10-09
Clock Bio–BY Capital: investment, 202410 seed financing round totalling $5.3m incl co-investor BlueYard Capital 2024-10-09
Clock Bio–Onsight Ventures: investment, 202410 seed financing round totalling $5.3m incl co-investor Onsight Ventures 2024-10-09
Clock Bio–PERSON: investment, 202410 seed financing round totalling $5.3m incl co-investor Jonathan Milner 2024-10-09
Clock Bio–Phoenix Court Group: investment, 202410 seed financing round totalling $5.3m incl lead investor LocalGlobe 2024-10-09
Clock Bio–SEVERAL: investment, 202410 seed financing round $5.3m led by LocalGlobe 2024-10-09
Purespring Therapeutics–ICR: public relations, 202410 service existent ICR Consilium is media contact 2024-10-09
Purespring Therapeutics–SEVERAL: investment, 202410 financing round Series B £80m led by Sofinnova Partners 2024-10-09
Bayer–Moma Therapeutics: drug discovery, 202410– collab + excl license option €na using KNOMTIC platform to discover small-molecule cancer drugs 2024-10-08
Lymphatica Medtech–SEVERAL: investment, 202410 financing round Series B €17.9m led by Panakès Partners + TechWald Next + CDP VC 2024-10-08
Somagenetix–MC Services: public relations, 202410 service existent by MC Services 2024-10-08
Somagenetix–Schroders: investment, 202410 financing round Series A totalling CHF10m first closing incl existing + co-investor Schroders Capital 2024-10-08
Somagenetix–SEVERAL: investment, 202410 financing round Series A CHF10m first closing led by Vi Partners 2024-10-08
Somagenetix–Verve Capital Partners: investment, 202410 financing round Series A totalling CHF10m first closing incl existing + co-investor Verve 2024-10-08
Somagenetix–Vi Partners: investment, 202410 financing round Series A totalling CHF10m first closing incl lead investor Vi Partners 2024-10-08
Somagenetix–Zürcher Kantonalbank: investment, 202410 financing round Series A totalling CHF10m first closing incl existing + co-investor ZKB 2024-10-08
Yumab–Molcure: AI-based drug discovery, 202410– collab expansion to incl zero-shot AI Ab discovery technology to discover Abs for undrugged targets 2024-10-08
Danaher–CrestOptics: spinning disk microscopy, 202410– collab integration of Cicero spinning disk unit into Thunder Imager of Leica Microsystems 2024-10-07
Enara Bio–Francis Crick Institute: investment, 202410 financing round Series B totalling $32.5m incl new + co-investor Francis Crick Institute 2024-10-03
Enara Bio–Merck (DE): investment, 202410 financing round Series B totalling $32.5m incl new + co-lead investor M Ventures 2024-10-03
Enara Bio–Pfizer: investment, 202410 financing round Series B totalling $32.5m incl new + co-lead investor Pfizer Ventures 2024-10-03
Enara Bio–RA Capital: investment, 202410 financing round Series B totalling $32.5m incl existing + co-investor RA Capital 2024-10-03
Enara Bio–Samsara BioCapital: investment, 202410 financing round Series B totalling $32.5m incl existing + co-investor Samsara BioCapital 2024-10-03
Enara Bio–SEVERAL: investment, 202410 financing round Series B $32.5m co-led by new investors Pfizer Ventures + M Ventures 2024-10-03
Enara Bio–SV Health Investors: investment, 202410 financing round Series B totalling $32.5m incl existing + co-investor SV Health Investors 2024-10-03
Kurma–SEVERAL: investment, 202410 first closing of Kurma Biofund IV with target for final closing of €250m 2024-10-03
Dynamic Biosensors–Bruker: investment, 202410 acquisition €na of Dynamic Biosensors GmbH + integration in Bruker Biosensors business 2024-10-02
LoQus23 Therapeutics–Forbion: investment, 202410 financing round Series A totalling £35m incl new + lead investor Forbion 2024-10-02
LoQus23 Therapeutics–Novartis: investment, 202410 financing round Series A totalling £35m incl existing + co-investor Novartis Venture Fund 2024-10-02
LoQus23 Therapeutics–Optimum Strategic Communications: public relations, 202410 service existent by Optimum 2024-10-02
LoQus23 Therapeutics–SEVERAL: investment, 202410 financing round Series A £35m led by new investor Forbion 2024-10-02
LoQus23 Therapeutics–SV Health Investors: investment, 202410 financing round Series A totalling £35m incl existing + co-investor DDF 2024-10-02
Aitiologic–Austria (govt): grant, 202306–202410 grants from aws + FFG 2024-10-01
Aitiologic–Lana Ventures: investment, 202306–202410 seed financing round incl co-lead investor LANA Ventures 2024-10-01
Aitiologic–Push Ventures: investment, 202306–202410 seed financing round incl co-lead investor PUSH VC 2024-10-01
Aitiologic–SEVERAL: investment, 202306–202410 seed financing round >€2.5m (incl aws + FFG grants) led by Push VC + Lana Ventures 2024-10-01
Erbe Elektromedizin–1BillionLives: quality management software, 202409 supply existent Erbe is customer of Flinn.ai 2024-09-30
Roche–Regor: CDK inhibitors, 202409– acquisition $850m cash upfront + milestones of portfolio of CDK inhibitors by Genentech from Regor 2024-09-30
Sequentia Biotech–BPCE: investment, 202409 financing round Series A totalling €10m incl lead investor Seventure Partners 2024-09-27
Sequentia Biotech–EU (govt): investment, 202409 financing round Series A totalling €10m incl co-investor EIC Fund 2024-09-27
Sequentia Biotech–SEVERAL: investment, 202409 financing round Series A €10m with Seventure Partners + EIC Fund 2024-09-27
Novo Group–Evotec: cell therapy manufacturing, 202409– collab technology development €na RnD funding + upfront + milestone payments plus royalties 2024-09-26
Resonac–Altaris: investment, 202409– acquisition 100% of Minaris Regenerative Medicine Subsidiaries of Resonac by Altaris LLC 2024-09-26
Genespire–Indaco: investment, 202409 financing round Series B totalling €46.6m incl co-investor Indaco SGR 2024-09-25
Genespire–Italy (govt): investment, 202409 financing round Series B totalling €46.6m incl co-lead investor CDP Venture Capital Large Venture Fund 2024-09-25
Genespire–SEVERAL: investment, 202409 financing round Series B €46.6m led by Sofinnova Partners + Xgen Venture + CDP Venture Capital 2024-09-25
Genespire–Sofinnova: investment, 202409 financing round Series B totalling €46.6m incl existing + co-lead investor Sofinnova Partners 2024-09-25
Genespire–Xgen Venture: investment, 202409 financing round Series B totalling €46.6m incl co-lead investor Xgen Venture 2024-09-25
Constructive Biology–SEVERAL: investment, 202409 financing round Series A first closing $58m led by Ahren + OMX Ventures + Paladin Capital 2024-09-24
Lift BioSciences–SEVERAL: investment, 202409 financing round Series A first closing £10m 2024-09-24
Shan Foods–Symrise: foods, 202409 strategic collab existent Pakistan + UAE + KSA incl joint production plant in Pakistan 2024-09-20
Noah Labs–Adesso: investment, 202409 seed financing round totalling less than €3m incl co-investor Adesso Ventures 2024-09-19
Noah Labs–Berlin (govt): investment, 202409 seed financing round totalling less than €3m incl co-investor DHZB Foundation 2024-09-19
Noah Labs–Brandenburg (govt): credit, 202409 loan from ILB ProFit Brandenburg funding programme 2024-09-19
Noah Labs–Brandenburg (govt): grant, 202409 grant from ILB ProFit Brandenburg funding programme 2024-09-19
Noah Labs–Nina Capital: investment, 202409 seed financing round totalling less than €3m incl lead investor Nina Capital 2024-09-19
Noah Labs–OTHER: investment, 202409 seed financing round totalling less than €3m incl range of business angels 2024-09-19
Noah Labs–SEVERAL: investment, 202409 seed financing round €3m (incl grant + loan from ILB) led by Nina Capital 2024-09-19
Austrian Academy of Sciences–Boehringer: grant, 202409–203608 funding €150m establishment + operation of AITHYRA Institute over 12y by BIS 2024-09-18
Roivant–Organon: investment, 202409– acquisition of Dermavant Sciences by Organon $175m upfront + $1.025b milestones plus royalties incl product Vtama 2024-09-18
ImmunOs Therapeutics–BioMedPartners: investment, 202409 financing round Series C totalling $11m incl existing + co-lead investor BioMed Partners 2024-09-17
ImmunOs Therapeutics–Double Point Ventures: investment, 202409 financing round Series C totalling $11m incl new + co-investor Double Point Ventures 2024-09-17
ImmunOs Therapeutics–Gimv: investment, 202409 financing round Series C totalling $11m incl existing + co-lead investor Gimv 2024-09-17
ImmunOs Therapeutics–Mission BioCapital: investment, 202409 financing round Series C totalling $11m incl existing + co-lead investor Mission BC 2024-09-17
ImmunOs Therapeutics–Pfizer: investment, 202409 financing round Series C totalling $11m incl existing + co-lead investor Pfizer Ventures 2024-09-17
ImmunOs Therapeutics–SEVERAL: investment, 202409 financing round Series C $11m led by Gimv + Pfizer Ventures ü+ Mission BioCapital + BioMedPartners 2024-09-17
Trials24–Subject Well: investment, 202409 acquisition of Trials24 by SubjectWell backed by PE firm WindRose Health 2024-09-17
Cell Signaling Technology–e-Blot Life Science: imaging system, 202409– distribution of Touch Imager system by Bioké in 12 European countries 2024-09-16
Symphera–Bavaria (govt): investment, 202409 seed financing round totalling €2.4m incl co-investor HTGF 2024-09-16
Symphera–Carma Fund: investment, 202409 seed financing round totalling €2.4m incl co-investor Carma Fund 2024-09-16
Symphera–High-Tech Gründerfonds: investment, 202409 seed financing round totalling €2.4m incl lead investor HTGF 2024-09-16
Symphera–IRCAD: investment, 202409 seed financing round totalling €2.4m incl co-investor IRCAD Strasbourg 2024-09-16
Symphera–OTHER: investment, 202409 seed financing round totalling €2.4m incl expert business angels from the medical field 2024-09-16
1 2 3 ... 81 82 83  next pagenext page



Advertisement

Picture biomindz TRON LSE Mainz Translation Cancer Immunotherapy 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Advertisement

Picture Berlin Partner Voices Tim Huse BIH Digital Health 650x300px

» top